The Alzheimer's Prevention Initiative (API) trial in cognitively healthy individuals has reached a significant milestone with the first participants in Colombia receiving doses of an experimental anti-amyloid antibody, crenezumab designed to delay or prevent the onset of Alzheimer's disease.

More...